Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Viventia's Cancer Ambitions Go To Eleven

Executive Summary

Merger with troubled ophthalmology biotech Eleven takes Viventia public and joins the protein-engineering and manufacturing expertise of the two firms. Lead candidate Vicinium is in Phase III for high-grade, non-muscle invasive bladder cancer.

Advertisement

Related Content

J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?
J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value
J.P. Morgan Executive Roundtable, Part 2: Women In Biopharma And The Path Forward
J.P. Morgan Executive Roundtable, Part 1: How To Help Women Move Into The Biopharma C-Suite
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Does Deal With Roche Signal Eleven's Doomed Fate?
Biotech IPO Window Closed In November As Returns And Prices Plunged
Eleven Biotherapeutics Shifts Focus After Trial Failure

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register